Gila Therapeutics, Inc.
Gila Therapeutics is a clinical stage biotech company pioneering a novel biological pathway, the tongue-brain connection, to develop safer and more effective treatments for obesity and cardiometabolic disorders. They leverage an unexploited neural signaling system to activate targeted brain areas involved in metabolic regulation, avoiding systemic exposure and side effects. Their first program, Topical Lingual PYY, has shown strong efficacy with no treatment-related adverse events, and they are developing multiple topical lingual hormone targets.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Topical lingual PYY therapeutic program
A topical lingual peptide program delivering micro-dose PYY via an orally disintegrating formulation to engage oral receptors and activate satiety-related brain regions without systemic exposure; completed Phase I with reported absence of treatment-related adverse events.
Topical lingual PYY therapeutic program
A topical lingual peptide program delivering micro-dose PYY via an orally disintegrating formulation to engage oral receptors and activate satiety-related brain regions without systemic exposure; completed Phase I with reported absence of treatment-related adverse events.
Services
Joint research and development collaborations with academic institutions and industry partners to advance topical lingual peptide programs.
Joint research and development collaborations with academic institutions and industry partners to advance topical lingual peptide programs.
Expertise Areas
- Topical/lingual drug delivery
- Peptide therapeutic development
- Targeted neural modulation for metabolic control
- Early-phase clinical development (Phase I)
Key Technologies
- Topical/lingual peptide delivery
- Orally disintegrating/orodispersible formulations
- Peptide therapeutics (PYY, GLP-1, amylin, leptin)
- Preclinical animal model testing